James Bristol
Chairman at ETERNA THERAPEUTICS INC.
Net worth: 390 100 $ as of 2024-04-29
Profile
James A.
Bristol is currently the Chairman-Medicinal Chemistry at Gordon Research Conferences.
He is also the Co-Chairman at Deciphera Pharmaceuticals LLC, the Chairman at Eterna Therapeutics, Inc., an Independent Director at Deciphera Pharmaceuticals, Inc., the Lead Independent Director at Erasca, Inc., a Director at Protypia, Inc., and a Senior Advisor at Frazier Management LLC.
In his former positions, Dr. Bristol served as an Independent Director at Ignyta, Inc. from 2014 to 2018, a Director at Sudo Biosciences, Inc. from 2021 to 2023, a Director at Cadent Therapeutics, Inc. from 2011 to 2021, and a Senior Vice President-Worldwide Discovery Research at Pfizer Inc. from 2003 to 2007.
He was also the Vice President-Discovery Research at Warner-Lambert Co. from 1980 to 2000.
Additionally, he held the position of Executive-in-Residence at Oxford Bioscience Partners and Vice President-Discovery Research at Pfizer (St. Louis) from 2003 to 2007.
He was a Member of The Polycystic Kidney Disease Research Foundation.
Dr. Bristol obtained his undergraduate degree from Bates College in 1968 and his doctorate degree from the University of New Hampshire in 1972.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ERASCA, INC.
0.14% | 2024-04-14 | 207,500 ( 0.14% ) | 390 100 $ | 2024-04-29 |
| 2024-03-30 | 0 ( -.--% ) | - $ | 2024-04-29 |
James Bristol active positions
| Companies | Position | Start |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Director/Board Member | 2023-08-02 |
| ERASCA, INC. | Director/Board Member | 2018-05-31 |
| ETERNA THERAPEUTICS INC. | Chairman | 2023-12-18 |
Protypia, Inc.
 Protypia, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million. | Director/Board Member | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Consultant / Advisor | 2008-12-31 |
| Gordon Research Conferences | Corporate Officer/Principal | - |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Chairman | 2009-03-24 |
Former positions of James Bristol
| Companies | Position | End |
|---|---|---|
Sudo Biosciences, Inc.
 Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Director/Board Member | 2023-11-30 |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Director/Board Member | 2020-12-31 |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of James Bristol
| University of New Hampshire | Doctorate Degree |
| Bates College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| ERASCA, INC. | Health Technology |
| ETERNA THERAPEUTICS INC. | Health Technology |
| Private companies | 11 |
|---|---|
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Pfizer (St. Louis)
 Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
| The Polycystic Kidney Disease Research Foundation | |
| Gordon Research Conferences | |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Finance |
Protypia, Inc.
Protypia, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million. | Commercial Services |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Technology Services |
- Stock Market
- Insiders
- James Bristol
